Simcere the first to market with iguratimod for RA
This article was originally published in Scrip
Executive Summary
Simcere Pharmaceutical is set to launch what it says will be the first iguratimod-containing product worldwide to be commercialised, following the approval of its version of the molecule in China for the treatment of rheumatoid arthritis (RA).